MCID: CLC006
MIFTS: 48

Calcinosis

Categories: Metabolic diseases

Aliases & Classifications for Calcinosis

MalaCards integrated aliases for Calcinosis:

Name: Calcinosis 12 29 54 43 15 71
Pathologically Calcified Structure 12
Pathologic Calcification 12

Classifications:



External Ids:

Disease Ontology 12 DOID:182
MeSH 43 D002114
NCIt 49 C3672
SNOMED-CT 67 6595006
UMLS 71 C0006663

Summaries for Calcinosis

Disease Ontology : 12 A calcium metabolism disease that is the result of the formation of calcium deposits in any soft tissue.

MalaCards based summary : Calcinosis, also known as pathologically calcified structure, is related to tumoral calcinosis, normophosphatemic, familial and tumoral calcinosis, hyperphosphatemic, familial, 1. An important gene associated with Calcinosis is SAMD9 (Sterile Alpha Motif Domain Containing 9), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Endochondral Ossification. The drugs Sevelamer and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Calcinosis is the formation of calcium deposits in any soft tissue. It is a rare condition that has many... more...

Related Diseases for Calcinosis

Diseases related to Calcinosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, normophosphatemic, familial 34.7 SAMD9L SAMD9
2 tumoral calcinosis, hyperphosphatemic, familial, 1 34.4 SAMD9 PHEX MEPE KL GALNT3 FGF23
3 familial tumoral calcinosis 34.2 TNF SAMD9L SAMD9 PHEX KL GALNT3
4 hyperparathyroidism 31.5 PHEX KL FGF23 CALCA
5 secondary hyperparathyroidism 31.3 PHEX KL FGF23 CALCA
6 calciphylaxis 31.1 SPP1 MGP FGF23 AHSG
7 hyperphosphatemia 31.0 SPP1 PHEX MGP KL GNAS GALNT3
8 kidney disease 31.0 SPP1 MGP FGF23 ENPP1 AHSG
9 hypoparathyroidism 30.9 GNAS FGF23 CALCA
10 primary hyperparathyroidism 30.8 KL FGF23 CALCA
11 angioid streaks 30.8 MGP GALNT3 ENPP1
12 hypervitaminosis d 30.8 KL GALNT3 FGF23 CALCA
13 scleroderma, familial progressive 30.6 FBN1 CENPB
14 bone resorption disease 30.5 TNF SPP1 FGF23 CALCA
15 osteitis fibrosa 30.5 GNAS FGF23 CALCA
16 uremia 30.5 TNF SPP1 MGP ENPP1 AHSG
17 skin atrophy 30.5 LMNA KL FGF23
18 dentin dysplasia 30.4 SPP1 MEPE DMP1
19 pulmonary alveolar microlithiasis 30.4 MEPE GALNT3 FGF23
20 hyperostosis 30.4 SPP1 KL GALNT3 FGF23 ANKH
21 hypophosphatemic rickets, x-linked recessive 30.3 PHEX MEPE FGF23 ENPP1 DMP1
22 nephrolithiasis 30.2 SPP1 MGP FGF23 AHSG
23 dental pulp calcification 30.1 SAMD9 KL GALNT3
24 arteriosclerosis 30.1 SPP1 MGP KL FBN1
25 bone disease 30.0 TNF SPP1 SPARC PHEX FGF23 CALCA
26 oncogenic osteomalacia 30.0 PHEX MEPE FGF23 DMP1
27 chronic kidney disease 30.0 TNF SPP1 MGP KL GNAS FGF23
28 rickets 30.0 SPP1 PHEX MEPE KL FGF23 ENPP1
29 tympanosclerosis 29.9 TNF SPP1 CALCA
30 enthesopathy 29.9 TNF PHEX MEPE KL FGF23 ENPP1
31 hypophosphatemic rickets, autosomal dominant 29.8 PHEX MEPE KL GALNT3 FGF23 ENPP1
32 nevus, epidermal 29.8 PHEX GNAS FGF23 ENPP1 DMP1
33 hypophosphatemia 29.8 SPP1 PHEX MEPE KL FGF23 ENPP1
34 osteomalacia 29.6 PHEX MEPE FGF23 ENPP1 DMP1 CALCA
35 diabetes mellitus 29.4 TNF SPP1 LMNA FGF23 ENPP1 CALCA
36 aortic valve disease 2 29.4 SPP1 SPARC MGP FBN1
37 ankylosis 29.4 TNF ENPP1 ANKH
38 hyperthyroidism 29.4 TNF GNAS CALCA
39 pseudoxanthoma elasticum 29.3 SPP1 SPARC MGP FBN1 ENPP1 ANKH
40 mccune-albright syndrome 29.2 SPARC GNAS FGF23 FBN1
41 osteoporosis 28.9 TNF SPP1 SPARC MGP MEPE LMNA
42 mineral metabolism disease 28.8 SPP1 PHEX MGP MEPE KL GALNT3
43 brittle bone disorder 28.8 SPP1 SPARC PHEX MEPE FBN1 CALCA
44 arterial calcification of infancy 28.5 SPP1 PHEX MGP KL GALNT3 FGF23
45 tumoral calcinosis, hyperphosphatemic, familial, 2 12.7
46 tumoral calcinosis, hyperphosphatemic, familial, 3 12.7
47 crest syndrome 12.2
48 basal ganglia calcification, idiopathic, childhood-onset 12.0
49 basal ganglia calcification, idiopathic, 1 12.0
50 mandibuloacral dysplasia with type a lipodystrophy 12.0

Graphical network of the top 20 diseases related to Calcinosis:



Diseases related to Calcinosis

Symptoms & Phenotypes for Calcinosis

GenomeRNAi Phenotypes related to Calcinosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.58 LMNA
2 Decreased viability GR00249-S 9.58 ANKH ENPP1 LMNA SPP1
3 Decreased viability GR00381-A-1 9.58 CALCA GNAS MGP
4 Decreased viability GR00381-A-2 9.58 MGP
5 Decreased viability GR00381-A-3 9.58 MGP
6 Decreased viability GR00386-A-1 9.58 ANKH GNAS KL LMNA SAMD9
7 Decreased viability GR00402-S-2 9.58 ENPP1 FBN1 TNF

MGI Mouse Phenotypes related to Calcinosis:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.44 AHSG ANKH CENPB DMP1 ENPP1 FBN1
2 homeostasis/metabolism MP:0005376 10.4 AHSG ANKH DMP1 ENPP1 FBN1 FGF23
3 cardiovascular system MP:0005385 10.39 ANKH DMP1 ENPP1 FBN1 FGF23 GALNT3
4 cellular MP:0005384 10.38 ANKH CENPB DMP1 ENPP1 FBN1 GALNT3
5 hematopoietic system MP:0005397 10.36 ANKH DMP1 FBN1 FGF23 GALNT3 GNAS
6 immune system MP:0005387 10.35 ANKH DMP1 ENPP1 FBN1 FGF23 GALNT3
7 craniofacial MP:0005382 10.34 ANKH DMP1 ENPP1 FBN1 GALNT3 GNAS
8 behavior/neurological MP:0005386 10.32 ANKH ENPP1 FBN1 GNAS KL LMNA
9 endocrine/exocrine gland MP:0005379 10.25 CENPB DMP1 FBN1 FGF23 GALNT3 GNAS
10 limbs/digits/tail MP:0005371 10.25 AHSG ANKH DMP1 ENPP1 FBN1 FGF23
11 integument MP:0010771 10.2 ENPP1 FBN1 FGF23 GALNT3 GNAS KL
12 mortality/aging MP:0010768 10.18 ANKH CENPB ENPP1 FBN1 FGF23 GNAS
13 adipose tissue MP:0005375 10.14 ENPP1 FBN1 GNAS KL LMNA PHEX
14 hearing/vestibular/ear MP:0005377 10.07 AHSG ANKH ENPP1 GNAS KL LMNA
15 muscle MP:0005369 10.06 AHSG ANKH ENPP1 FBN1 GALNT3 GNAS
16 renal/urinary system MP:0005367 10 DMP1 ENPP1 FBN1 FGF23 GALNT3 GNAS
17 liver/biliary system MP:0005370 9.95 ENPP1 GNAS KL LMNA PHEX SPP1
18 reproductive system MP:0005389 9.85 ANKH CENPB DMP1 FBN1 FGF23 GALNT3
19 respiratory system MP:0005388 9.61 ANKH FBN1 FGF23 GNAS KL LMNA
20 skeleton MP:0005390 9.53 AHSG ANKH DMP1 ENPP1 FBN1 FGF23

Drugs & Therapeutics for Calcinosis

Drugs for Calcinosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
Calcium acetate Approved, Investigational Phase 4 62-54-4
4
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
5
Ethanol Approved Phase 4 64-17-5 702
6 fluindione Approved, Investigational Phase 4 957-56-2
7
Dalteparin Approved Phase 4 9005-49-6
8
Phenindione Approved, Investigational Phase 4 83-12-5 4760
9
Apixaban Approved Phase 4 503612-47-3 10182969
10
Amlodipine Approved Phase 4 88150-42-9 2162
11
Phylloquinone Approved, Investigational Phase 4 84-80-0
12
Warfarin Approved Phase 4 81-81-2 6691 54678486
13
Rivaroxaban Approved Phase 4 366789-02-8
14
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
15
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
16
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
17
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
18
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
19
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
20 Menaquinone Investigational Phase 4 1182-68-9
21
Coumarin Experimental Phase 4 91-64-5 323
22 Vasodilator Agents Phase 4
23 Antihypertensive Agents Phase 4
24 Vasoconstrictor Agents Phase 4
25 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
26 Liver Extracts Phase 4
27 calcium channel blockers Phase 4
28 Butylated Hydroxytoluene Phase 4
29 Heparin, Low-Molecular-Weight Phase 4
30 Antivitamins K Phase 4
31 Antioxidants Phase 4
32 Protective Agents Phase 4
33 Hemostatics Phase 4
34 Antifibrinolytic Agents Phase 4
35 Coagulants Phase 4
36 naphthoquinone Phase 4
37 Vitamin K Phase 4
38 Vitamin K 2 Phase 4
39 Antithrombins Phase 4
40 Antithrombin III Phase 4
41 Serine Proteinase Inhibitors Phase 4
42 Factor Xa Inhibitors Phase 4
43
protease inhibitors Phase 4
44 HIV Protease Inhibitors Phase 4
45 Anticoagulants Phase 4
46 retinol Phase 4
47 Retinol palmitate Phase 4
48 Pharmaceutical Solutions Phase 4
49
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
50
Magnesium hydroxide Approved, Investigational Phase 2, Phase 3 1309-42-8

Interventional clinical trials:

(show top 50) (show all 147)
# Name Status NCT ID Phase Drugs
1 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
2 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
3 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
4 A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
5 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
6 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial Completed NCT02610933 Phase 4 rivaroxaban
7 A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4 Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
8 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
9 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Completed NCT00261625 Phase 4 alendronate
10 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
11 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
12 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
13 Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality]) Completed NCT00124969 Phase 4 Amlodipine;Placebo
14 Effects of Melatonin on Progression of Coronary Artery Calcification Recruiting NCT03966235 Phase 4 Melatonin 3 mg;Placebo
15 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: a Randomized Controlled Trial, Extension Study Active, not recruiting NCT03799822 Phase 4 Rivaroxaban 10 MG Oral Tablet;Vitamin K Antagonist - Drug
16 Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial) Active, not recruiting NCT02066662 Phase 4 Rivaroxaban or Marcumar
17 A Comparative Study of the Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Normal Saline for the Treatment of Dystrophic and Idiopathic Calcinosis Cutis, A Double-Blind Randomized Placebo-Controlled Trial Terminated NCT03639779 Phase 4 Sodium Thiosulfate
18 A Prospective, Randomized, Open-Label Trial Investigating the Effect of 1 Alpha Hydroxy Vitamin D2 on the Development of Coronary Calcification in New ESRD Patients Using the 1-84/7-84 PTH Ratio to Determine Dosing Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
19 The Effect of Oral Magnesium Supplementation on Vascular Calcification in Chronic Kidney Disease - A Randomized Clinical Trial Unknown status NCT02542319 Phase 2, Phase 3
20 Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Unknown status NCT01000233 Phase 2, Phase 3
21 Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT) Completed NCT01683500 Phase 3
22 Vitamin K Containing Nutritional Supplement for Activation of Matrix-GIa-proteins (MGP) and Inhibition of Aortic Valve Calcification Process Completed NCT00785109 Phase 3
23 Food Supplementation With Vitamin K2 to Activate MGP as an Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients Completed NCT01407601 Phase 3
24 Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients Completed NCT03314493 Phase 3 Spironolactone 25Mg Tablet
25 Randomized Prospective Open Interventional Multi-centre Study on Finding the Optimal Dose of Vitamin K2 Supplements for Hemodialysis Patients Completed NCT01675206 Phase 3
26 Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study Completed NCT00481364 Phase 3 atorvastatin;placebo
27 Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification Completed NCT00183001 Phase 3 Vitamin K
28 The Use of Bisphosphonates to Prevent or Delay the Progression of Vascular Calcification in End-Stage Renal Disease: A Randomized Controlled Trial Completed NCT00687661 Phase 3 Bisphosphonate;Placebo
29 Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study Recruiting NCT03689946 Phase 3 Evolocumab
30 The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery. Not yet recruiting NCT04408430 Phase 2, Phase 3
31 A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial Terminated NCT03150420 Phase 3 Sodium Thiosulfate;Placebo-Normal Saline
32 Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease Unknown status NCT01364688 Phase 2 oral alfacalcidol;no drug
33 Phase II Study of Calcitonin for Tumoral Calcinosis Completed NCT00004358 Phase 2 calcitonin
34 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
35 A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis Completed NCT02663895 Phase 2 Oral treprostinil
36 Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients Completed NCT02790073 Phase 2 SNF472
37 The Treatment Effect of Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis Completed NCT00720772 Phase 2 25% intravenous (IV) sodium thiosulfate
38 A Phase II Randomized, Placebo-Controlled, Double-Blinded Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification in Patients With Moderate Calcific Aortic Valve Stenosis Completed NCT02481258 Phase 2 Ataciguat (HMR1766)
39 A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD) Completed NCT02966028 Phase 2 SNF472;Placebo
40 The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial Completed NCT02977117 Phase 2
41 SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis Completed NCT02132026 Phase 2 Denosumab;Alendronic Acid;Denosumab Placebo;Alendronic Acid Placebo
42 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
43 The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease Recruiting NCT03960437 Phase 2 Etelcalcetide
44 Efficacy of Sodium Thiosulfate in Shoulder Pain in Calcific Tendinitis of the Rotator Cuff Recruiting NCT04251832 Phase 2 Sodium Thiosulfate
45 Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study Recruiting NCT02830204 Phase 2
46 A Comparative Trial of Calcitriol Versus Placebo for the Preservation of Bone Mass and Strength After Kidney Transplantation Active, not recruiting NCT02224144 Phase 2 Vitamin D3;Calcitriol;Placebo
47 Treatment to Reduce Vascular Calcification In Hemodialysis Patients Using Vitamin K Active, not recruiting NCT02870829 Phase 2 menaquinone-7
48 Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialysis Patients: The iPACK-HD Study Active, not recruiting NCT01528800 Phase 2 Vitamin K1;Microcrystalline Methylcellulose
49 An Open-label, Non-Randomized, Single-Arm Pilot Study to Evaluate the Effectiveness of Etidronate Treatment for Arterial Calcifications Due to Deficiency in CD73 (ACDC) Active, not recruiting NCT01585402 Phase 2 Etidronate
50 The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients Not yet recruiting NCT03301558 Phase 2 Low dose sodium bicarbonate;High dose sodium bicarbonate

Search NIH Clinical Center for Calcinosis

Cochrane evidence based reviews: calcinosis

Genetic Tests for Calcinosis

Genetic tests related to Calcinosis:

# Genetic test Affiliating Genes
1 Calcinosis 29

Anatomical Context for Calcinosis

MalaCards organs/tissues related to Calcinosis:

40
Kidney, Bone, Skin, Heart, Breast, Brain, Liver

Publications for Calcinosis

Articles related to Calcinosis:

(show top 50) (show all 3799)
# Title Authors PMID Year
1
Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. 61 54
18448482 2008
2
Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. 61 54
17050587 2006
3
Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression. 54 61
16847207 2006
4
A homozygous mutation in the lamin A/C gene associated with a novel syndrome of arthropathy, tendinous calcinosis, and progeroid features. 54 61
16278265 2006
5
Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. 54 61
10849372 2000
6
Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. 61 54
10756089 2000
7
[Diabetic macroangiopathy in humans]. 61 54
9501570 1997
8
von Willebrand factor in juvenile dermatomyositis. 54 61
7738956 1995
9
Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. 54 61
8129780 1994
10
Idiopathic scrotal calcinosis: A new case report. 61
32382511 2020
11
MR imaging findings of calcinosis cutis in primary Sjogren syndrome, a rare manifestation. 61
32435323 2020
12
[Juvenile dermatomyositis: A series of 22 cases]. 61
32532518 2020
13
[Etiology, therapy and prophylaxis of bovine parturient paresis (hypocalcaemia)]. 61
32557514 2020
14
Anatomical and histological characteristics of the hepatobiliary system in adult Sox17 heterozygote mice. 61
32478476 2020
15
Lumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case. 61
32556288 2020
16
Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. 61
31586421 2020
17
Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. 61
32487712 2020
18
Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. 61
32234404 2020
19
Shockwave™ lithoplasty in combination with atherectomy in treating severe calcified femoropopliteal and iliac artery disease: A single center experience. 61
32563711 2020
20
Multiple Autoimmune Syndrome: An Unusual Combination of Autoimmune Disorders. 61
32564761 2020
21
Secondary Tumoral Calcinosis of the Larynx. 61
32436401 2020
22
Milia-Like Idiopathic Calcinosis Cutis: When Waiting Is the Best Option. 61
32437759 2020
23
Surgical Management of Idiopathic Ulcerative Calcinosis Cutis in the Lower Extremity: A Case Report. 61
31732275 2020
24
Calcinosis cutis. 61
32145957 2020
25
Breast calcinosis in a patient with dermatomyositis. 61
31680358 2020
26
A Case of Dermatomyositis Coexisting with Both Anti-Mi-2 and Anti-NXP-2 Antibodies. 61
32508616 2020
27
[Pseudotumoral calcinosis of the wrist compressing the radial nerve in systemic sclerosis]. 61
31952956 2020
28
Systemic sclerosis-related calcinosis can affect the breast - but malignancy should always be excluded. 61
32456568 2020
29
Ultrasound Detection of Calcinosis and Association with Ulnar Artery Occlusion in Patients with Systemic Sclerosis. 61
32475057 2020
30
Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis. 61
32360901 2020
31
Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. 61
32432645 2020
32
Clinical Images: Tumoral calcinosis mimicking tophi. 61
32281292 2020
33
Treatment of Uremic Tumoral Calcinosis in Maintenance Hemodialysis Patients. 61
32289781 2020
34
Subcutaneous granuloma annulare mimicking dermatomyositis. 61
32314413 2020
35
Diffuse Lacy Reticular Calcinosis in Juvenile Dermatomyositis. 61
32251056 2020
36
Treatment of hypophosphatasia. 61
32072352 2020
37
Scleroderma in Cairns: an epidemiological study. 61
31157951 2020
38
A pilot study of cutaneous oxygenation and perfusion in systemic sclerosis-related digital calcinosis. 61
32259842 2020
39
Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres. 61
32336495 2020
40
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. 61
32293539 2020
41
Tumoral calcinosis in systemic lupus erythematosus associated with fat necrosis. 61
31867787 2020
42
'Narrow-sense' and 'broad-sense' vascular abnormalities of systemic sclerosis. 61
32324110 2020
43
Case reports of benign intrascrotal tumors: Two epidermoid cysts and one scrotal calcinosis. 61
32255328 2020
44
Musculoskeletal hand involvement in systemic sclerosis. 61
31812353 2020
45
Calcinosis cutis of the face, mandible and neck. 61
31504983 2020
46
Epidemiology and Treatment of Calcinosis Cutis: 13 Years of Experience. 61
32180595 2020
47
Characterizing calcinosis cutis in a pediatric population. 61
31990419 2020
48
Iatrogenic calcinosis cutis secondary to calcium chloride successfully treated with topical sodium thiosulfate. 61
32149171 2020
49
A 52-Year-Old Female with Multiple Swellings in Both Hands: Idiopathic Calcinosis Cutis. 61
32351849 2020
50
Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal. 61
32115665 2020

Variations for Calcinosis

Expression for Calcinosis

Search GEO for disease gene expression data for Calcinosis.

Pathways for Calcinosis

Pathways related to Calcinosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.52 KL GNAS FGF23
2 11.25 SPP1 MGP ENPP1
3 11.13 TNF SPP1 CALCA
4 10.79 TNF SPP1 CALCA
5 10 TNF SPP1 MEPE GNAS FGF23 FBN1

GO Terms for Calcinosis

Cellular components related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 TNF SPP1 SPARC KL FGF23 FBN1
2 endoplasmic reticulum lumen GO:0005788 9.63 SPP1 MEPE FGF23 FBN1 DMP1 AHSG
3 extracellular region GO:0005576 9.44 TNF SPP1 SPARC MGP MEPE KL
4 extracellular matrix GO:0031012 9.43 SPARC MGP MEPE FBN1 DMP1 AHSG

Biological processes related to Calcinosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.85 SPP1 MEPE FGF23 FBN1 DMP1 AHSG
2 extracellular matrix organization GO:0030198 9.83 TNF SPP1 SPARC FBN1 DMP1
3 fibroblast growth factor receptor signaling pathway GO:0008543 9.73 KL GALNT3 FGF23
4 skeletal system development GO:0001501 9.73 PHEX MEPE GNAS FBN1 ANKH AHSG
5 ossification GO:0001503 9.72 SPP1 SPARC MGP DMP1 AHSG
6 bone development GO:0060348 9.7 SPARC PHEX GNAS
7 cellular protein metabolic process GO:0044267 9.7 SPP1 MEPE FGF23 FBN1 DMP1 CALCA
8 response to vitamin D GO:0033280 9.59 SPP1 PHEX
9 negative regulation of glucose import GO:0046325 9.58 TNF ENPP1
10 energy reserve metabolic process GO:0006112 9.58 KL GNAS
11 negative regulation of bone mineralization GO:0030502 9.58 FGF23 ENPP1 AHSG
12 cellular response to vitamin D GO:0071305 9.57 PHEX FGF23
13 cellular response to parathyroid hormone stimulus GO:0071374 9.55 PHEX FGF23
14 cellular phosphate ion homeostasis GO:0030643 9.54 FGF23 ENPP1
15 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.51 KL FGF23
16 sequestering of triglyceride GO:0030730 9.49 TNF ENPP1
17 response to sodium phosphate GO:1904383 9.48 PHEX FGF23
18 inorganic diphosphate transport GO:0030505 9.46 ENPP1 ANKH
19 biomineral tissue development GO:0031214 9.35 SPP1 PHEX MEPE ENPP1 DMP1
20 regulation of bone mineralization GO:0030500 9.02 MGP FGF23 ENPP1 ANKH AHSG

Molecular functions related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.63 SPARC MGP GALNT3 FBN1 ENPP1 DMP1
2 hormone activity GO:0005179 9.43 KL FBN1 CALCA
3 extracellular matrix structural constituent GO:0005201 9.26 SPARC MGP MEPE FBN1
4 extracellular matrix binding GO:0050840 8.8 SPP1 SPARC DMP1

Sources for Calcinosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....